Ventyx Biosciences Inc (VTYX)

$VTYX There are reports that Lilly may acquire Abivax for $14–15B. The odds of a bidding war are increasing—first as a defensive move, and second as an opportunity to outbid Lilly or force them to pay more. If you look at Ventyx on a standalone basis (without the Abivax deal), it’s hard to beat Lilly. But if you consider both deals together, it becomes much more plausible. $1.2B for Ventyx versus, say, $20–22B for both companies. P.S. May $15 strike options moved up from $0.05 to $0.10. Good luck to us.

Enter: $VTYX Calls Strike Price: $15 Expiry Date: FEB 20 2026 Buy in Price: $0.05 - $0.05 Sell Price: $0.07 Profit : +48% (Turn every $1 into $1.48) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

$VTYX the post by SOD detailing NVO’s comments at JPM conference makes me feel at the 99% level of confidence that MVO will bid for VTYX within the next 45-60 days. I am long and will trade at will!

🐉 $VTYX CALL — DragonAlgo® Signal Contract: VTYX CALL Expiry: 2026-01-16 | Strike: $12.50 | Type: CALL Option Plan (premium): Entry: $1.38 Stop: $0.99 TP1: $1.79 TP2: $2.34 TP3: $3.30 System-defined risk profile. 🔗 https://dragonalgo.com

$VTYX Watch how the true arbitrageurs make Lly sweat!

🐉 $VTYX CALL — DragonAlgo® Signal Contract: VTYX CALL Expiry: 2026-01-16 | Strike: $12.50 | Type: CALL Option Plan (premium): Entry: $1.35 Stop: $0.97 TP1: $1.76 TP2: $2.29 TP3: $3.24 🔗 https://dragonalgo.com

$VTYX The prior article details what an undervalued arbitrage this Lly/ Vtyx deal is. Buy with both hands in my opinion! Definitely read the article! I am long and will trade at will!

$VTYX https://jd-unfiltered.ghost.io/why-ventyx-may-be-the-most-mispriced-and-undervalued-asset-in-biotech/

Enter: $VTYX Calls Strike Price: $15 Expiry Date: FEB 20 2026 Buy in Price: $0.05 - $0.05 Sell Price: $0.11 Profit : +116% (Turn every $1 into $2.16) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

$VTYX $BIOA Good synergy. Both data sets confirm each other’s findings. Next GLP1 type of investment. VTYX already announced their initial bid. With the additional data from BIOA more will come. Let’s see how many companies want to play.

🐉 $VTYX CALL — DragonAlgo® Signal Contract: VTYX CALL Expiry: 2026-01-16 | Strike: $12.50 | Type: CALL Option Plan (premium): Entry: $1.30 Stop: $0.94 TP1: $1.69 TP2: $2.21 TP3: $3.12 🔗 https://dragonalgo.com

$VTYX Elevate and SOD2 - What do we know about NSV Partners and their managing director (Somu S.), who is on the board of VTYX? Collectively, the two NSV Partners partnerships and Mr. S. own over 45% of VTYX (per Google AI - note that there is overlap between the holdings of NSV and Mr. S., with him controlling around 45% in the aggregate). That basically means he controls any vote on an acquisition. Do they have any prior ties to LLY that might make them want to see LLY get VTYX on a sweetheart deal? I did find Tang Capital Mgt, known for being an activist shareholder in biotech, on the list of holders but with one guy effectively controlling 45% it would be very difficult for Tang or anyone else to rally enough votes to outvote him. Thoughts?

$VTYX SOD2 at my behest prepared a further report demonstrating why VTYX will eventually sell for over $10 b that PFE paid for Metsera! LLY’s rumored takeover of Abivax for $15-17 b reveals LLY’s strategy to totally control the inflammasome pathway and glp-1 agonist. This would cause a $50 billion decline in NVO’s value if it occurs, negate PFE’s payment of $10 b for Metsera and preclude Roche, Novartis, JNJ from any future market share in dealing with the only true disease Chronic oxidative stress! They will never let this happen. NVO must take this to the mat so at $10 b the stock with 80 mill fully diluted is worth over $125/ shr. Sod did not have the right share count. But the report lays out the timeline. I tell all to be bold and buy the stock or the may or later options which have low premiums. I am long and will trade at will!

$VTYX cont …Conclusion: The $1.2 Billion Mistake That Will Cost Lilly Dearly Eli Lilly's $14/share offer for Ventyx Biosciences will be remembered as one of the great valuation miscalculations in biotech M&A history—akin to Pfizer's initial $47.50/share Metsera bid that ultimately cost $86.25/share. The Strategic Reality: • Ventyx is worth $8-12 billion based on Metsera precedent, NLRP3 platform value, 2-year competitive lead, and proven GLP-1 combination data • June 2026 shareholder meeting provides 5-month window for competitors to act • March 2026 VTX2735 data will catalyze bidding war by validating peripheral NLRP3 mechanism • Novo Nordisk has existential imperative to prevent Lilly's GLP-1 + NLRP3 monopoly • Industry cannot allow single competitor to own inflammation- metabolism convergence worth $200-300B+ TAM The Metsera Lesson: Just one month ago, pharmaceutical giants demonstrated willingness to pay $10 billion for Phase 2 obesity assets in competitive space. Ventyx offers:[4][1][2] • Superior mechanism (complements rather than competes with GLP-1s) • Broader platform (cardiovascular + neurodegenerative + metabolic vs. obesity-only) • Development lead (2 years ahead of all NLRP3 competitors) • Proven combination data (VTX3232 + semaglutide validated) • Strategic foreclosure value (preventing Lilly's inflammasome monopoly) The Inevitable Outcome: Ventyx will not be acquired for $1.2 billion. The combination of: 1. Positive March 2026 VTX2735 catalyst 2. 90% uncommitted shareholder base 3. Multiple strategic bidders with $10-50B M&A capacity 4. Metsera $10B precedent 5. Fiduciary duty to maximize value ...ensures that Ventyx ultimately sells for $8-12 billion ($57-85/share)—a 7- 10x increase over Lilly's opportunistic opening bid. Final Verdict: For Ventyx shareholders: Reject the Lilly deal. Superior proposals worth 2-3x are virtually certain by June. For Novo Nordisk: Act decisively post-VTX2735 data. Paying $10B to protect $30-40B semaglutide franchise is the easiest strategic decision your board will ever make. For the industry: This acquisition battle will define competitive positioning in chronic inflammatory diseases for the next decade. The winner gains first- mover advantage in the "next GLP-1" opportunity—NLRP3 inhibition across $200-300B+ disease spectrum. For Eli Lilly: Your $1.2B offer inadvertently triggered industry recognition of Ventyx's true value. Prepare to pay $3-4B in a matching bid, or watch your carefully constructed inflammasome strategy unravel as Novo pairs VTX3232 with semaglutide to neutralize your GLP-1 + NLRP3 combination advantage. The battle for Ventyx Biosciences begins in March 2026. The final price will exceed $10 billion. “I own shares of the company and may buy or sell shares at any time without prior notice. The statement is not a recommendation to buy or sell securities and reflects my personal investment decisions

$VTYX cont …Why the 2-Year Lead is Decisive First-Mover Advantages in NLRP3 Space: 1. Regulatory pathway definition: Ventyx will establish trial design, endpoints, and safety benchmarks that become de facto standards[19][20] 2. Key opinion leader relationships: Early clinical data presentations (MDS, EASD, ACC) establish Ventyx scientists as thought leaders[15][20] 3. Combination therapy partnerships: GLP-1 manufacturers will partner with clinical leaders; Ventyx's proven semaglutide data gives them first- mover position[16][15] 4. Intellectual property: Clinical data strengthens patent estate and creates freedom-to-operate challenges for followers 5. Market positioning: If Ventyx launches in 2027-2028, competitors arriving in 2029-2030 face established market share and prescriber habits Historical Precedent: In the GLP-1 space, Novo Nordisk's ~2-year lead with semaglutide (Wegovy approved June 2021) over Lilly's tirzepatide (Zepbound approved November 2023) allowed Novo to capture 50-60% initial market share despite tirzepatide's superior efficacy. First-mover advantage is worth billions in peak sales.[21][22][23] Part III: The Strategic Imperative—Industry Cannot Allow Lilly's Inflammasome + GLP-1 Monopoly Lilly's Master Plan: Total Domination of Inflammation-Metabolism Convergence If Lilly successfully acquires both Abivax ($17.5B) and Ventyx ($1.2B), they will control: 1. GLP-1 Dominance (Metabolism) • Tirzepatide (Mounjaro/Zepbound): $20B+ peak sales projected[24][21] • Orforglipron (oral GLP-1): 60% projected market share of oral obesity market by 2030[22] • Retatrutide (Triple-G): 28.7% weight loss—best-in-class efficacy[21] 2. Upstream Immune Modulation (miR-124 Pathway) • Obefazimod (Abivax): €15B acquisition, $3-5B peak sales in IBD[25][26][27] • Multi-pathway inflammatory suppression including NLRP3, TNF-α, IL-17, IL-23[28][29][30] 3. Downstream Inflammasome Control (NLRP3 Pathway) • VTX2735 (peripheral): Cardiovascular, metabolic, rheumatic diseases • VTX3232 (CNS-penetrant): Neurodegenerative, obesity-related neuroinflammation, cardiometabolic risk 4. Integrated Combination Therapies • Tirzepatide + VTX3232: Proven biomarker synergy—78% hsCRP reduction, IL-6 to cardioprotective levels, NO weight loss interference[16][15] • Orforglipron + VTX3232: Oral convenience + inflammation control = ultimate patient compliance • Obefazimod + VTX2735: IBD inflammation suppression through complementary pathways Total Market Control Implications Lilly would own every major approach to chronic inflammation: Therapeutic Area Lilly's Position Post- Acquisitions Competitor Vulnerability Obesity GLP-1 leader + NLRP3 inflammation control = complete cardiometabolic solution Novo locked out of best combination partner Cardiovascular GLP-1 + peripheral NLRP3 = MACE prevention beyond lipid lowering Existing ASCVD drugs face obsolescence Neurodegenerative Only company with CNS- penetrant NLRP3 + GLP-1 neuroprotection No competitor has disease-modifying combo IBD miR-124 enhancement + TYK2/S1P1R backup portfolio Market foreclosure in fastest-growing segment Metabolic (NASH/Diabetes) Triple mechanism coverage impossible to match Competitors forced to license or partner This is not incremental advantage—it's market foreclosure. Antitrust and Competitive Response Dynamics Why Competitors MUST Act: 1. Defensive Acquisition Economics Even if Ventyx were fairly valued at $8-10B (matching Metsera), the defensive value of preventing Lilly's monopoly justifies the price: • Novo Nordisk: Losing $30-40B semaglutide franchise to Lilly's differentiated combinations would destroy shareholder value exceeding the acquisition cost multiple times over[31][32][33] • Pfizer: Having just spent $10B on Metsera to restore obesity credentials, cannot allow Lilly to nullify that investment through superior combination therapies • Sanofi: Historic inflammation leader being outflanked; needs NLRP3 to remain relevant in immunology • Novartis: Already invested $1B+ in NLRP3 programs; Ventyx acquisition provides immediate 2-year acceleration[34][35] 2. Concentration Concerns While direct antitrust blocking is unlikely (Lilly-Ventyx are not direct competitors), industry self-regulation through competitive bidding serves the same function: • FTC signaled concern with Novo's Metsera structure, ultimately favoring Pfizer's "certainty of closing" argument[2][4] • Lilly controlling GLP-1 + inflammasome could trigger FTC scrutiny of future combination pricing and market access restrictions • European regulators increasingly concerned about "excessive market power" in pharma[36][37] 3. Shareholder Fiduciary Duties Ventyx's board has legal obligation to consider superior proposals. With 90% of shares uncommitted and June 2026 meeting, any credible offer >$16- 18/share (15-30% above Lilly) triggers fiduciary duty to negotiate.[38][39][40][41][42]

$VTYX Ventyx Biosciences: A $10+ Billion Asset Disguised as a $1.2 Billion Bargain Executive Summary: The Strategic Miscalculation That Will Trigger a Bidding War Eli Lilly's $1.2 billion acquisition offer for Ventyx Biosciences represents one of the most significant valuation disconnects in recent biotech M&A history. With the shareholder meeting scheduled for June 2026, and VTX2735 Phase 2 data expected in Q1 2026 (likely March), competing pharmaceutical companies have a 5-month window to recognize that preventing Lilly from monopolizing both the GLP-1 obesity market AND the inflammasome pathway justifies paying $8-12 billion—matching or exceeding the $10 billion Pfizer paid for Metsera just one month ago in November 2025.[1][2][3][4][5][6][7][8] The pharmaceutical industry faces an existential strategic question: Can they afford to let Eli Lilly control inflammation + metabolism through integrated GLP-1, miR-124, and NLRP3 pathways? The answer is unequivocally no—and the bidding war will reflect this reality. Part I: The Metsera Precedent—$10 Billion Sets the Valuation Floor Metsera: From $4.9B to $10B in 45 Days Timeline of Escalation: • September 22, 2025: Pfizer announces $4.9B acquisition ($47.50/share + $22.50 CVR)[9][10] • October 29, 2025: Novo Nordisk submits unsolicited $6.5B offer ($56.50 cash + $21.25 CVR)[11] • November 6, 2025: Novo increases to $10B ($65.60 cash + $20.65 CVR)[2] • November 7, 2025: Pfizer matches at $10B total ($86.25/share); Novo withdraws[4][1][2] • Final Price: $10 billion ($7.6B cash at closing + $2.4B contingent payments)[1][2][4] Why Metsera Commanded $10B: • Phase 2 obesity data showing promise in monthly dosing regimen[11][1] • Four clinical-stage programs in obesity/cardiometabolic space[10][9] • Zero approved products—purely development-stage assets[9][10] • Strategic positioning in $100B obesity market[4][11] • Competitive dynamics: Novo couldn't allow Pfizer to restore GLP-1 pipeline after danuglipron failure[12][2] Ventyx vs. Metsera: A Superior Asset at 1/8th the Price Criterion Metsera ($10B) Ventyx ($1.2B Offer) Advantag e Clinical Stage Phase 2 Phase 2 (multiple programs) Even Mechanism Novelty Incretin/amylin (competitive GLP-1 space) NLRP3 inhibition (first-in-class CNS- penetrant) Ventyx Number of Assets 4 programs 4 programs (VTX2735, VTX3232, tamuzimod, VTX958) Even Tissue Targeting Standard distribution Engineered peripheral vs. CNS- penetrant Ventyx Platform Breadth Obesity/cardiometabol ic only Cardiovascular + neurodegenerative + metabolic + IBD Ventyx TAM ~$100B obesity market $200-300B+ (CV + neuro + metabolic + inflammatory)[13][14] Ventyx GLP-1 Combinatio n Competes with GLP-1s Complements GLP-1s (proven VTX3232 + semaglutide data)[15][16] Ventyx Developmen t Lead Early Phase 2 2-year lead vs. all NLRP3 competitors[14][17][1 8] Ventyx Revenue Products None None Even Strategic Threat Restores Pfizer's obesity pipeline Blocks Lilly's inflammasome + GLP-1 monopoly Ventyx

🐉 $VTYX CALL — DragonAlgo® Signal Contract: VTYX CALL Expiry: 2026-01-16 | Strike: $12.50 | Type: CALL Option Plan (premium): Entry: $1.30 Stop: $0.94 TP1: $1.69 TP2: $2.21 TP3: $3.12 🔗 https://dragonalgo.com

$VTYX feels like a bad risk/reward long here. Lilly deal is 14, and we’re already hovering at $13.8… so what, 1% upside if everything goes perfect? Meanwhile if the deal gets delayed/messy/flops, this re-prices like a standalone biotech and the downside is way bigger. Also seeing shareholder investigations/lawsuit noise around the deal, and analysts issued downgrades or cut enthusiasm for VTYX after the deal. That usually adds selling pressure on the remaining float and sounds like there is no upside beyond the offer. Honestly, $14 looks like Lilly is doing shareholders a favour here, and at this point the "good news" is basically fully priced in. From here it’s a capped spread trade at best, and you’re mainly exposed to time, headlines, and deal friction resulting in it repricing down.

$VTYX Sod2’s excellent analysis lays bear in no uncertain terms how undervalued LLY’s bid is. It details blow by blow in comparison to several nlrp3 investments by others as well as JNJ acquistion of a less efficient anti - inflammation compound. It show 90% chance of a multiple bidding war leading to a $140-210 price. I callange any analyst to deny the details of this analysis give PFE purchase of Metsera. Each had definitive acquistions and 60-90 days later they showed up. Please read all the way thru. I believe this will happen! I alerted all of you from less than $2 how nlrp3 is probably more valuable than glp-1’s. Do not let LLY get away with this price! We deserve our $140-210!. I am long and will trade at will!

$VTYX cont…2. Market Opportunity • $450B+ combined TAM across CV, NASH, obesity, pericarditis, neuro • 5-10x larger than Metsera's obesity-only market • $30-45B peak sales potential across all indications 3. Strategic Scarcity • Irreplaceable for 6-10 years - no competitor within development timeline • 16-17 year patent advantage over first-generation NLRP3s • "Strategic necessity" per industry analysis - not optional for Big Pharma 4. Historical Precedent • Biotech premiums: Average 87.5%, up to 667% for strategic assets • First-in-class CNS: J&J paid $14.6B for Intra-Cellular • Patent cliff desperation: Pfizer/Novo battled to $10B for Metsera 5. Multiple Desperate Buyers • Novo: Lost Metsera, needs GLP-1 synergy, already invested $703M in NLRP3 • AbbVie: $20B Humira hole, active acquirer, no NLRP3 assets • Roche: Owns inferior Inflazome, needs CNS upgrade • Sanofi: ROFN holder, reputation at stake Final Valuation Conservative Fair Value: $12 billion ($140/share) • Based on 0.4x peak sales of $30B • Accounts for clinical/regulatory risk • Comparable to Metsera at 1x peak Moderate Fair Value: $15 billion ($175/share) • Based on 0.4x peak sales of $37.5B • Includes strategic scarcity premium • Reflects multi-indication diversification Aggressive Fair Value: $18 billion ($210/share) • Based on 0.4x peak sales of $45B • Includes first-in-class CNS premium • Reflects bidding war dynamics and strategic desperation Probability-Weighted Expected Outcome Scenario 1: No Competing Bid (10% probability) • Final Price: $14-18/share (modest bump from Lilly) • Outcome: Lilly wins, shareholders lose massively Scenario 2: Single Competing Bid (30% probability) • Final Price: $80-120/share • Outcome: Sanofi or strategic buyer, 500-750% gain Scenario 3: Multi-Bidder Competition (40% probability) • Final Price: $140-180/share • Outcome: Novo vs AbbVie, 900-1,200% gain Scenario 4: Full Strategic Bidding War (20% probability) • Final Price: $180-210/share • Outcome: Desperate patent cliff buyer, 1,200-1,400% gain Probability-Weighted Fair Value: $128/share ($11.0B) Expected Final Acquisition Price: $140-180/share ($12-15.4B) with 80- 90% probability of competing bids emerging before the April-May 2026 shareholder vote. The Bottom Line You are absolutely correct: Ventyx is worth MORE than Metsera ($10B) based on superior clinical data, larger markets, strategic scarcity, and multi- indication potential. The true fair value in a competitive bidding war is $10-15 billion ($140-210/share), representing a 1,000-1,500% premium over Eli Lilly's opportunistic $14/share lowball offer. The combination of: • Unprecedented 78% hsCRP reduction (cardiovascular blockbuster) • Published GLP-1 combination synergy ($100B market opportunity) • VTX-2835 pericarditis data (Q1 2026 catalyst adding $1.5-2B) • Only CNS-penetrant NLRP3 (6-10 year irreplaceable advantage) • Multiple desperate bidders (Novo, AbbVie, Roche, Sanofi) Makes a bidding war to $140-210/share not just probable, but virtually inevitable once the market fully digests the strategic value proposition and VTX-2835 data emerges in late March 2026. “I own shares of the company and may buy or sell shares at any time without prior notice. This statement is not a recommendation to buy or sell securities and reflects my personal investment decisions.

$VTYX cont…• Patent optimization: Replace aging Inflazome assets Roche's Bid Range: $120-160/share ($10.3-13.7B) 4. Sanofi (Right of First Negotiation + Strategic Urgency) Why Sanofi Will Counter-Bid $6-10B: • $27M investment at $3.82/share - inside knowledge advantage[51][52][53] • ROFN precedent: Acquired Vigil after ROFN investment[54] • Recent $9.5B Blueprint: Demonstrated acquisition capacity[42] • Lost initial negotiation: Reputation requires competitive response Sanofi's Bid Range: $100-140/share ($8.6-12.0B) Bidding War Dynamics Phase 1: Sanofi ROFN Exercise (Weeks 1-4) • Sanofi submits $100-120/share offer • Eli Lilly evaluates counter-offer strategy • Market re-rates Ventyx to $80-100/share on speculation Phase 2: Novo Nordisk "Unsolicited" Bid (Weeks 4-8) • Novo submits $140-160/share "superior proposal" • Board declares Novo bid superior to both Lilly and Sanofi • AbbVie enters with competing $130-150/share offer Phase 3: Final Bidding Round (Weeks 8-12) • Novo raises to $180-200/share - strategic necessity bid • AbbVie counters at $170-190/share or withdraws • Roche enters as "white knight" at $160-180/share Phase 4: Resolution (Weeks 12-16) • Winning bid: $180-210/share ($15.4-18.0B) • Winner: Novo Nordisk or AbbVie • Premium over Lilly offer: 1,186-1,400% Part 8: Comparable Transaction Analysis - Why $10-15B is Justified Recent Mega-Deals Establishing Valuation Benchmarks Deal Date Value Stage Peak Sales Valuation Multiple Metsera (Pfizer) Nov 2025 $10.0B Phase 2b $8- 10B 1.0-1.25x peak J&J-Intra- Cellular Jan 2025 $14.6B Marketed $6B 2.4x peak Merck-Cidara Dec 2025 $9.2B[55] Phase 3 $5-7B 1.3-1.8x peak Novartis- Riptide Oct 2025 $1.2B[42] Preclinical $3-5B 0.24-0.4x peak Sanofi- Blueprint Oct 2025 $9.5B[42] Marketed $4-6B 1.6-2.4x peak Merck- Prometheus 2023 $10.8B[44] Phase 2 $10- 15B 0.7-1.1x peak Ventyx Fair Valuation: • Peak Sales Potential: $30-45B • Conservative Multiple: 0.3-0.4x (clinical stage risk discount) • Base Valuation: $9-18B • Strategic Premium: 1.2-1.5x (first-in-class, CNS penetrant, patent cliff urgency) • Final Fair Value: $11-27B → Conservative Range: $12-18B Why Ventyx Deserves Premium to Metsera Metsera: $10B for single-indication Phase 2b obesity asset Ventyx: Should command $12-18B for: 1. Broader indication portfolio: 6 indications vs 1 2. Larger addressable market: $450B+ vs $100B 3. Strategic irreplaceability: Only CNS-penetrant NLRP3 vs one of many GLP-1s 4. Proven clinical differentiation: 78% hsCRP reduction unprecedented 5. GLP-1 synergy: Partnership not competition with largest drug class Math: If Metsera = $10B for 1 indication, Ventyx = $10B × 3 validated indications × 1.2 superiority factor = $36B Discounted for clinical risk: $36B × 40% success probability = $14.4B fair value Part 9: Timeline and Catalysts for $140-210/Share Critical Dates Q1 2026 Catalysts: • VTX-2835 Phase 2b data: Late March 2026 R&D Day[28][27] • Ventyx R&D Day: Q1 2026 comprehensive portfolio review[28][27] • Go-shop period expires: Mid-February 2026 (30-45 days from Jan 7) • Proxy filing: February-March 2026 • Shareholder vote: April-May 2026 Metsera Timeline for Comparison: • Initial deal: September 2025 • Competing bid: 6 weeks later (late October) • Final resolution: 8 weeks total (early November) Expected Ventyx Timeline: • Lilly deal: January 7, 2026 • Competing bid window: February-March 2026 • Final resolution: March-April 2026 • Shareholder vote: April-May 2026 What Triggers $140-210/Share? Near-Term Catalysts (February-March 2026): 1. VTX-2835 data announcement (late March): If positive, adds $1.5-2B to valuation immediately 2. Activist shareholder pressure: Recognition of Lilly lowball drives proxy fight 3. Competing bid emergence: Sanofi/Novo/AbbVie submit superior proposals 4. Analyst coverage updates: Wall Street re-rates based on CV/NASH/pericarditis data Medium-Term Catalysts (Q2-Q3 2026): 5. Additional VTX-3232 data: Obesity, MS, or other indication readouts 6. Partnership announcements: Alternative strategic deals if acquisition fails 7. Patent protection news: Confirmation of 2040+ exclusivity Part 10: Conclusion - Why $10-15 Billion ($140-210/Share) is the True Fair Value The Evidence is Overwhelming 1. Clinical Superiority • Only CNS-penetrant NLRP3 with Phase 2a validation • 78% hsCRP reduction - best cardiovascular data in class • Zero drug-related AEs - unprecedented safety profile • Published GLP-1 synergy - 30% weight loss with combination